Evidence mapPaperPMID 39722964Full record

ArticleJournal of family medicine and primary care2024

Evaluating the metformin use on type 2 diabetes prevention in high-risk populations in primary care.

Neri A Álvarez-Villalobos, Andony I Ramírez-Torres, Fernando G Ruiz-Hernández, Gabriela G Elizondo Omaña, Rosa M García-Hernández, Pablo J Moreno Peña, Sandra S Rojo-Garza

Abstract read
In one paragraph

Article in Journal of family medicine and primary care, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Metformin Beyond Glycemic Control: Cardiovascular Protection and Diabetes Prevention.Journal of cardiovascular development and disease · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Neri A Álvarez-VillalobosDepartment of Education, Family Medicine Unit Number 7, Instituto Mexicano del Seguro Social (IMSS), San Pedro Garza García, N.L., Mexico.
Andony I Ramírez-TorresDepartment of Education, Family Medicine Unit Number 7, Instituto Mexicano del Seguro Social (IMSS), San Pedro Garza García, N.L., Mexico.
Fernando G Ruiz-HernándezCentro de Desarrollo de Investigación 360, Faculty of Medicine, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico.
Gabriela G Elizondo OmañaDepartment of Education, Family Medicine Unit Number 64, Instituto Mexicano del Seguro Social (IMSS), Santa Catarina, N.L., Mexico.
Rosa M García-HernándezDepartment of Education, Family Medicine Unit Number 7, Instituto Mexicano del Seguro Social (IMSS), San Pedro Garza García, N.L., Mexico.
Pablo J Moreno PeñaCentro de Desarrollo de Investigación 360, Faculty of Medicine, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico.
Sandra S Rojo-GarzaDepartment of Education, Family Medicine Unit Number 7, Instituto Mexicano del Seguro Social (IMSS), San Pedro Garza García, N.L., Mexico.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose/Background: To identify the proportion of patients with prediabetes who have prescribed metformin and factors related to doing so as a preventive measure for diabetes in primary care at a Family Medicine Unit in northeastern Mexico. Methods: This retrospective observational study included 372 adults who met the criteria for prediabetes diagnosis according to the American Diabetes Association. Data was collected from medical records from January 2020 to December 2021. Possible associations between the variables of interest and the prescription of metformin were tested via hypothesis tests, furthermore, binary logistic regression was performed. Results: Nearly 85% of the patients met at least one criterion for receiving metformin according to ADA recommendations, but only 60% of them were prescribed this medication. Patients with metformin prescriptions differed from those without in aspects such as having a documented diagnosis of prediabetes in their medical records, a higher BMI, and higher glucose levels. Conclusions: Almost one out of two patients with a high risk of type 2 diabetes are not treated with metformin as a preventive measure. Factors associated with metformin prescription included a high BMI, elevated baseline glucose levels, and a prediabetes diagnosis in the medical record. These findings suggest the need for studies to evaluate physicians' reasons for different treatments and implementation of recommendations for type 2 diabetes prevention in patients with prediabetes in primary health care.

Indexed as

Diabetes mellitusdiabetes mellitus type 2guideline adherencemetforminprediabetesprediabetic stateprimary health caresecondary prevention

Identifiers

PMID39722964
PMCPMC11668474

What Socratic holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.